Details
 

August 30, 2016
6:30PM - 8:30PM

Keytruda Update

Webinar

You are cordially invited to participate in a national webcast.

Keytruda is indicated for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. 

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Learning Objectives:
• Provide an overview of HNSCC and review the role of the immune system in cancer
• Review clinical data on KEYTRUDA for the treatment of patients with recurrent or metastatic HNSCC
• Identify patients with recurrent or metastatic HNSCC appropriate for treatment with KEYTRUDA

For more information, Click Here.

Printer-Friendly Version